There appears to be an interesting trial just starting at Henri Mondor Hospital in Creteil France involving ProSavin gene therapy. The first patient is being injected about now and efficacy should be demonstrated within a few weeks although results are not due until June. if the results are as positive as preclinical then we should hear news before then.

From Oxford Biomedica website
CLINICAL STATUS
ProSavin is currently being evaluated in a Phase I/II trial in France. Long-term efficacy data in the industry-standard preclinical model of Parkinson's disease have shown that ProSavin induces almost complete recovery from movement disorders and restores other behavioural and metabolic measurements to near normal levels.